Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response

A point mutation in the BRAF gene, leading to a constitutively active form of the protein, is present in 45%–60% of patients and acts as a key driver in melanoma. Shortly after therapy induction, resistance to MAPK pathway-specific inhibitors develops, indicating that pathway inhibition is circumven...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernhardt, Mathias, Novak, Daniel, Assenov, Yassen, Orouji, Elias, Knappe, Nathalie, Weina, Kasia, Reith, Maike, Larribere, Lionel, Gebhardt, Christoffer, Plass, Christoph, Umansky, Viktor, Utikal, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425615/
https://www.ncbi.nlm.nih.gov/pubmed/28392221
http://dx.doi.org/10.1016/j.stemcr.2017.03.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425615/
https://www.ncbi.nlm.nih.gov/pubmed/28392221
http://dx.doi.org/10.1016/j.stemcr.2017.03.007

Ejemplares similares